Stefanie Huhn
Overview
Explore the profile of Stefanie Huhn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lutz R, Poos A, Sole-Boldo L, John L, Wagner J, Prokoph N, et al.
Sci Immunol
. 2025 Feb;
10(104):eadp6667.
PMID: 39919199
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However,...
2.
Mai E, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2402266.
PMID: 39652594
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of...
3.
Maura F, Kaddoura M, Poos A, Baughn L, Ziccheddu B, Bartsch M, et al.
bioRxiv
. 2024 Sep;
PMID: 39282268
To comprehensively unravel the temporal relationship between initiating and driver events and its impact on clinical outcomes, we analyzed 421 whole-genome sequencing profiles from 382 patients. Using clock-like mutational signatures,...
4.
Kriegsmann K, Ton G, Awwad M, Benner A, Bertsch U, Besemer B, et al.
Leukemia
. 2024 Jun;
38(7):1621-1625.
PMID: 38830959
No abstract available.
5.
Cirrincione A, Poos A, Ziccheddu B, Kaddoura M, Bartsch M, Maclachlan K, et al.
Blood
. 2024 May;
144(7):771-783.
PMID: 38728430
Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these...
6.
Mai E, Goldschmid H, Miah K, Bertsch U, Besemer B, Hanel M, et al.
Lancet Haematol
. 2024 Feb;
11(2):e101-e113.
PMID: 38302221
Background: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well...
7.
Schreiner S, Berghaus N, Poos A, Raab M, Besemer B, Fenk R, et al.
Amyloid
. 2024 Jan;
31(2):86-94.
PMID: 38206120
Background: AL amyloidosis (AL) results from the misfolding of immunoglobulin light chains (IG LCs). Aim of this study was to comprehensively analyse kappa LC sequences from AL patients in comparison...
8.
Zhao D, Rohde C, Gollner S, Zhou F, Pauli C, Blank M, et al.
Leukemia
. 2023 Oct;
37(12):2526-2531.
PMID: 37845284
No abstract available.
9.
John L, Poos A, Brobeil A, Schinke C, Huhn S, Prokoph N, et al.
Nat Commun
. 2023 Aug;
14(1):5011.
PMID: 37591845
In multiple myeloma spatial differences in the subclonal architecture, molecular signatures and composition of the microenvironment remain poorly characterized. To address this shortcoming, we perform multi-region sequencing on paired random...
10.
Poos A, Prokoph N, Przybilla M, Mallm J, Steiger S, Seufert I, et al.
Blood
. 2023 Jun;
142(19):1633-1646.
PMID: 37390336
Intratumor heterogeneity as a clinical challenge becomes most evident after several treatment lines, when multidrug-resistant subclones accumulate. To address this challenge, the characterization of resistance mechanisms at the subclonal level...